Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γσ T cells

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8710-8717

  Shojaei, Hamed ^a   Oberg, Hans Heinrich ^a   Juricke, Matthias ^a   Marischen, Lothar ^a   Kunz, Monika ^a   Mundhenke, Christoph ^a   Gieseler, Frank ^a   Kabelitz, Dieter ^a   Wesch, Daniela ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; GRANZYME A; GRANZYME B; IMIQUIMOD; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOGENESIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; NEOPLASMS; POLY I-C; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 7;

EID: 72249091840     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1602     Document Type: Article

References (44)

1. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunol Immunother 2007;56:1285-1297 (Pubitemid 46763941)
2. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human {γδ} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7457 (Pubitemid 47206575)
3. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-392
4. Espinosa E, Belmant C, Pont F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γ δ T cells. J Biol Chem 2001;276:18337-18344 (Pubitemid 37411407)
5. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-168 (Pubitemid 36152311)
6. Bonneville M, Scotet E. Human Vγ9Vδ2 T cells: promising newl eads for immunotherapy of infections and tumors. Curr Opin Immunol 2006;18:539-546 (Pubitemid 44311448)
7. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of Vγ9Vδ2 T cells by NKG2D. J Immunol 2005;175:2144-2151
8. Wrobel P, Shojaei H, Schittek B, et al. Lysis of a broad range of epithelial tumour cells by human γα T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2Ddependent recognition. Scand J Immunol 2007;66:320-328 (Pubitemid 47063194)
9. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729 (Pubitemid 129505074)
10. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133 (Pubitemid 32206515)
11. O'Connor GM, Hart OM, Gardiner CM. Putting the natural killer cell in its place. Immunology 2006;117: 1-10.
12. Halary F, Peyrat MA, Champagne E, et al. Control of self-reactive cytotoxic T lymphocytes expressing γδT cell receptors by natural killer inhibitory receptors. Eur J Immunol 1997;27:2812-2821 (Pubitemid 27478348)
13. Wesch D, Kabelitz D. Differential expression of natural killer receptors on Vδ1 γδ T cells in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2003;33:420-425 (Pubitemid 36886071)
14. Guo BL, Liu Z, Aldrich WA, Lopez RD. Innate antibreast cancer immunity of apoptosis-resistant human γδ-T cells. Breast Cancer Res Treat 2005;93:169-175 (Pubitemid 41396778)
15. Beetz S, Wesch D, Marischen L, Welte S, Oberg HH, Kabelitz D. Innate immune functions of human γδ T cells. Immunobiology 2008;213:173-182
16. Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, Kabelitz D. Direct costimulatory effect of TLR3 ligand poly(I:C) on human γδT lymphocytes. J Immunol 2006;176:1348-1354 (Pubitemid 43134276)
17. Kawai T, Akira S. TLR signaling. Semin Immunol 2007;19:24-32.
18. Paulos CM, Kaiser A, Wrzesinski C, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007; 13:5280-5289
19. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008;13: 859-875
20. Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008;27:168-180
21. Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 2008;57:1271-1278
22. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-738 (Pubitemid 33009951)
23. Soria I, Myhre P, Horton V, et al. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther 2000;38:476-481 (Pubitemid 30765591)
24. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human Vγ9Vδ2γδ T cells in vitro and in SCID mice in vivo. J Immunol 2004;173: 6767-6776 (Pubitemid 39541063)
25. Kabelitz D, Wesselborg S. Life and death of a superantigen- reactive human CD4+ T cell clone: staphylococcal enterotoxins induce death by apoptosis but simultaneously trigger a proliferative response in the presence of HLA-DR+ antigen-presenting cells. Int Immunol 1992;4:1381-1388 (Pubitemid 23005955)
26. Janssen O, Wesselborg S, Heckl-Ostreicher B, et al. T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor γδ+ T cells. J Immunol 1991; 146:35-39
27. CaccamoN, Meraviglia S, Cicero G, et al. Aminobisphosphonates as neww eapons for γδ T cell-based immunotherapy of cancer. Curr Med Chem 2008;15:1147-1153
28. Burjanadze M, Condomines M, Reme T, et al. In vitro expansion of γ δ T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007;139:206-216
29. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheralexpanded Vγ9Vδ2 T cells from renal cell carcinoma patients. J Immunother 2008;31:313-323
30. Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell γδ, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008;57: 1599-1609
31. Bouet-Toussaint F, Cabillic F, Toutirais O, et al. Vγ9Vδ2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 2008;57:531-539
32. Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int J Cancer 2006;119:2359-2365 (Pubitemid 44546956)
33. Pries R, Hogrefe L, Xie L, et al. Induction of c-Mycdependent cell proliferation through Toll-like receptor 3 in head and neck cancer. Int J Mol Med 2008;21: 209-215 (Pubitemid 351222854)
34. Kistowska M, Rossy E, Sansano S, et al. Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR γδ cells. Eur J Immunol 2008;38:2200-2209
35. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-4901
36. Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004;9:291-298 (Pubitemid 38986952)
37. Inglefield JR, Larson CJ, Gibson SJ, Lebrec H, Miller RL. Apoptotic responses in squamous carcinoma and epithelial cells to small-molecule Toll-like receptor agonists evaluated with automated cytometry. J Biomol Screen 2006;11:575-585 (Pubitemid 44315955)
38. Smith EB, Schwartz M, Kawamoto H, et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol 2007;177:2347-2351 (Pubitemid 46726385)
39. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007;13: 4565-4574
40. Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006;20:1138-1144 (Pubitemid 43797309)
41. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006; 20:1130-1137 (Pubitemid 43797308)
42. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006;66:3859-3868
43. Skinner R. Role of topical therapies in the management of cutaneous disease. J Cutan Med Surg 2004;3: 22-31. (Pubitemid 40685110)
44. Jasani B, Navabi H, Adams M. Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27:3401-3404